FARMINGDALE, N.Y., May 27, 2015 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international ultrasonic surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic instruments for spine surgery, neurosurgery and other surgical specialties, announces the publication of two articles featuring the BoneScalpel in Becker's Spine Review, May 2015. Becker's Spine Review features news and analysis on business and legal issues relating to spine practices. Each issue of the quarterly publication reaches a qualified audience of approximately 12,500 key spine practice decision-makers including surgeons and spine practice administrators.
The Misonix BoneScalpel is an ultrasonic bone-cutting instrument that provides a clean, controlled bone incision and removal that is also soft-tissue sparing. The two Becker's Spine Review articles feature the use of the BoneScalpel technology in spinal deformity and minimally-invasive spine procedures.
Jessica Cole, President and Chief Executive Officer of Becker's Healthcare, said, "Our team searches for various cutting-edge, novel technologies that are known to have a positive impact on surgeons and patients. We strive to be a resource for the spine community and feature these new technologies and products in our various publications."
The spinal deformity article discusses the beneficial impact the BoneScalpel has on procedure outcomes and patient safety as compared to traditional instruments, like drills and burrs. "It [the BoneScalpel] replaces a lot of other tools I would use about 80 percent of the time," said Isador Lieberman, MD, Director of the Scoliosis and Spine Tumor Center, Texas Back Institute, Plano, TX. "The other instruments we have are high-speed, rotating burrs and if you get too close to the nerve or dura, you rip the tissue. I don't have that issue with the BoneScalpel."
The minimally invasive spine surgery article positions the BoneScalpel as an enabling technology that has many benefits for both the surgeon and the patient. "It does matter whether you decompress with a drill or ultrasonic BoneScalpel because the BoneScalpel offers controlled movements when you're working close to important organs," said Daniel Rosenthal, MD, Director of Spine Surgery at Bad Homburg Regional Hospital in Frankfort, Germany. "Using the ultrasonic technology is safer for your patients and it's less stressful for the surgeon because they aren't pulling and twisting with their hands like they would with other instruments."
Juan Uribe, MD, Director of the Complex and Minimally-Invasive Spine Section in the Department of Neurosurgery at the University of South Florida, said, "The BoneScalpel has changed the way I perform minimally-invasive spine procedures. It enables a more effective decompression of the lateral recess and foramen than I was able to do with traditional instruments. My procedures are also more efficient with the BoneScalpel as I now only require one instrument to perform the decompression, where as in the past, I was using multiple instruments."
"We are pleased that Becker's Spine Review has elected to feature our BoneScalpel ultrasonic technology," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "These articles very clearly illustrate the benefits that our BoneScalpel brings to spine surgery."
About Misonix Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used in spine surgery, neurosurgery, orthopedic surgery, wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.
Safe Harbor Statement With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.
SOURCE Misonix, Inc.